Hadi Najah R, Al-Amran Fadhil, Hussein Mohammad A A, Rezeg Fadhil A
Department of Pharmacology, Medical College Kufa University, Najaf, Iraq.
J Cardiovasc Dis Res. 2012 Jan;3(1):5-11. doi: 10.4103/0975-3583.91592.
Atherosclerosis is an inflammatory disease of the blood vessel wall, characterized in early stages by endothelial dysfunction, recruitment and activation of monocyte/macrophages. Glimepiride is one of the third generation sulphonylurea drugs, useful for control of diabetes mellitus type two and it may exert anti inflammatory activity, by induction of nitric oxide production or through selective suppression of the cyclooxygenase pathway. Repaglinide is a new hypoglycemic agent, and a member of the carbamoylmethyl benzoic acid family. Some results from the literature demonstrate that repaglinide has favorable effects on the parameters of antioxidative balance.
The objective of the present study was to assess the effect of glimepiride and repaglinide on atherosclerosis via interfering with the inflammatory and oxidative pathways.
Twenty four local domestic male rabbits were involved in this study. The animals were randomly divided into four groups; Group I rabbits fed normal chow (oxiod) diet for 10 weeks. Group II rabbits were fed with 1% cholesterol enriched diet. Group III rabbits were fed with 1% cholesterol enriched diet together with Glimepiride (0.1 mg/kg once daily before morning feed). Group IV rabbits were fed with 1% cholesterol enriched diet together with Repaglinide (0.3 mg/kg once daily before morning feed). Blood samples were collected before (0 time) and every two weeks of experimental diets for measurement of serum triglycerides (TG), total cholesterol (TC), High-density lipoprotein cholesterol (HDL-C), high sensitive C - reactive protein (hsCRP), Interleukin - 6 (IL-6) and Tumor Necrosis Factor alpha (TNF-α) levels. At the end of 10 weeks, the aorta was removed for measurement of aortic Malondialdehyde (MDA), reduced glutathione (GSH) and aortic intimal thickness.
Glimepiride and repaglinide treatment did show significant effect on lipid parameters compared with induced untreated group (P < 0.05). Also, they significantly reduced the elevation in hsCRP, IL-6, TNF-α, aortic MDA and aortic intimal thickness compared with induced untreated group (P < 0.05), and they helped to restore the aortic GSH levels (P < 0.05).
Glimepiride and repaglinide may reduce atherosclerosis progression in hypercholesterolemic rabbits by interfering with the inflammatory and oxidative pathways without affecting lipid parameters.
动脉粥样硬化是一种血管壁的炎症性疾病,早期特征为内皮功能障碍、单核细胞/巨噬细胞的募集和激活。格列美脲是第三代磺酰脲类药物之一,可用于控制2型糖尿病,它可能通过诱导一氧化氮生成或选择性抑制环氧化酶途径发挥抗炎活性。瑞格列奈是一种新型降糖药,属于氨甲酰甲基苯甲酸家族。文献中的一些结果表明,瑞格列奈对氧化平衡参数有有利影响。
本研究的目的是通过干扰炎症和氧化途径来评估格列美脲和瑞格列奈对动脉粥样硬化的影响。
本研究纳入了24只本地雄性家兔。动物被随机分为四组;第一组家兔喂食普通饲料(oxiod)10周。第二组家兔喂食富含1%胆固醇的饲料。第三组家兔喂食富含1%胆固醇的饲料并同时给予格列美脲(每天早上喂食前0.1mg/kg)。第四组家兔喂食富含1%胆固醇的饲料并同时给予瑞格列奈(每天早上喂食前0.3mg/kg)。在实验饮食前(0周)以及每两周采集血样,用于测定血清甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、高敏C反应蛋白(hsCRP)、白细胞介素-6(IL-6)和肿瘤坏死因子α(TNF-α)水平。在10周结束时,取出主动脉用于测定主动脉丙二醛(MDA)、还原型谷胱甘肽(GSH)和主动脉内膜厚度。
与未治疗的诱导组相比,格列美脲和瑞格列奈治疗对血脂参数有显著影响(P<0.05)。此外,与未治疗的诱导组相比,它们显著降低了hsCRP、IL-6、TNF-α、主动脉MDA和主动脉内膜厚度的升高(P<0.05),并且有助于恢复主动脉GSH水平(P<0.05)。
格列美脲和瑞格列奈可能通过干扰炎症和氧化途径来减少高胆固醇血症家兔的动脉粥样硬化进展,而不影响血脂参数。